PET Mapping of Neurofunctional Changes in a Posttraumatic Stress Disorder Model

J Nucl Med. 2016 Sep;57(9):1474-7. doi: 10.2967/jnumed.116.173443. Epub 2016 Mar 16.

Abstract

Posttraumatic stress disorder (PTSD) is an anxiety disorder that occurs after exposure to a traumatic event. This study aimed to investigate the neurobiologic changes before and after exposure-based therapy by PET in a rat model of PTSD.

Methods: Serial (18)F-FDG PET imaging studies were performed under the control (tone presentation), fear-conditioning, and extinction retrieval phases. Neuroactivity marker c-Fos protein was used for immunostaining.

Results: Increased glucose metabolism was observed in the bilateral amygdala after fear-conditioning (P < 0.001) and in the right posterior insular cortex under extinction retrieval (P < 0.001) compared with the control phase. Increased c-Fos expression in the posterior insular cortex under extinction retrieval was positively correlated to the glucose metabolism (P < 0.01).

Conclusion: Our results indicated that the amygdala plays a key role in fear memory formation and, most importantly, the insular cortex is related to the retrieval of extinction memory. (18)F-FDG PET may provide a promising in vivo approach for evaluating exposure-based therapy of PTSD.

Keywords: extinction; fear conditioning; positron emission tomography (PET); post-traumatic stress disorder (PTSD).

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Brain Mapping / methods*
  • Fluorodeoxyglucose F18 / pharmacokinetics*
  • Image Interpretation, Computer-Assisted / methods*
  • Male
  • Nerve Net / diagnostic imaging
  • Nerve Net / physiopathology
  • Positron-Emission Tomography / methods*
  • Radiopharmaceuticals / pharmacokinetics
  • Rats
  • Rats, Sprague-Dawley
  • Reproducibility of Results
  • Sensitivity and Specificity
  • Stress Disorders, Post-Traumatic / diagnostic imaging*
  • Stress Disorders, Post-Traumatic / physiopathology*

Substances

  • Radiopharmaceuticals
  • Fluorodeoxyglucose F18